Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology

Advanced Drug Delivery Reviews

Volumn 73, Issue , 2014, Pages 127-139

  Barker, Charlotte I S ^a,b   Germovsek, Eva ^b   Hoare, Rollo L ^b,c   Lestner, Jodi M ^a,d   Lewis, Joanna ^b,c   Standing, Joseph F ^b,c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antibacterial; Antifungal; Antimicrobial; Antiviral (and antiretrovirals); HIV viral and T cell dynamics; Immune reconstitution; Non linear mixed effects (NLME); Paediatrics; Pharmacokinetics pharmacodynamics (PKPD)

Indexed keywords

COMPUTER SIMULATION; IMMUNOLOGY; T-CELLS; DISEASES; PHARMACOKINETICS;

ANTI-FUNGAL; ANTIBACTERIAL; ANTIMICROBIAL; ANTIRETROVIRALS; IMMUNE RECONSTITUTION; NONLINEAR MIXED EFFECTS; PAEDIATRICS; T CELL DYNAMICS;

PEDIATRICS;

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; ANIDULAFUNGIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; FLUCLOXACILLIN; FLUCONAZOLE; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; ITRACONAZOLE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; MICAFUNGIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; QUINOLONE DERIVATIVE; TIMENTIN; UNINDEXED DRUG; VORICONAZOLE; ACICLOVIR; ALPHA INTERFERON; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CASPOFUNGIN; CEPHALOSPORIN DERIVATIVE; ECHINOCANDIN; GANCICLOVIR; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBAVIRIN; SIALIDASE INHIBITOR; ANTIINFECTIVE AGENT;

ANAEROBIC INFECTION; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTHROPATHY; BACTERIAL INFECTION; CHILD; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INVASIVE ASPERGILLOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PEDIATRICS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SURGICAL INFECTION; ABDOMINAL INFECTION; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CHRONIC HEPATITIS C; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C; IMMUNOCOMPROMIZED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA A; INFLUENZA B; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; MENINGITIS; MINIMUM PLASMA CONCENTRATION; MYCOSIS; NONHUMAN; OPTIMAL DRUG DOSE; PHARMACOKINETICS; VIRUS INFECTION; VIRUS LOAD; ANIMAL; BIOLOGICAL MODEL; COMMUNICABLE DISEASE; METABOLISM;

ANIMALS; ANTI-INFECTIVE AGENTS; CHILD; COMMUNICABLE DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MODELS, BIOLOGICAL; PEDIATRICS;

EID: 84902328965     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.01.002     Document Type: Review

References (204)

1. Lee J.Y., Garnett C.E., Gobburu J.V., Bhattaram V.A., Brar S., Earp J.C., Jadhav P.R., Krudys K., Lesko L.J., Li F., Liu J., Madabushi R., Marathe A., Mehrotra N., Tornoe C., Wang Y., Zhu H. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin. Pharmacokinet. 2011, 50:627-635.
2. Ette E.I., Williams P.J. Population pharmacokinetics II: estimation methods. Ann. Pharmacother. 2004, 38:1907-1915.
3. Ette E.I., Williams P.J. Population pharmacokinetics I: background, concepts, and models. Ann. Pharmacother. 2004, 38:1702-1706.
4. Ette E.I., Williams P.J., Lane J.R. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann. Pharmacother. 2004, 38:2136-2144.
5. Bonate P.L. Recommended reading in population pharmacokinetic pharmacodynamics. AAPS J. 2005, 7:E363-E373.
6. Anderson B.J., Allegaert K., Holford N.H. Population clinical pharmacology of children: general principles. Eur. J. Pediatr. 2006, 165:741-746.
7. Anderson B.J., Allegaert K., Holford N.H. Population clinical pharmacology of children: modelling covariate effects. Eur. J. Pediatr. 2006, 165:819-829.
8. Tod M., Jullien V., Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet. 2008, 47:231-243.
9. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2004, 2:289-300.
10. Moore R.D., Lietman P.S., Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 1987, 155:93-99.
11. Waxman D.J., Strominger J.L. Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics. Annu. Rev. Biochem. 1983, 52:825-869.
12. Bayles K.W. The bactericidal action of penicillin: new clues to an unsolved mystery. Trends Microbiol. 2000, 8:274-278.
13. Doogue M.P., Polasek T.M. Drug dosing in renal disease, the clinical biochemist. Rev. Aust. Assoc. Clin. Biochem. 2011, 32:69-73.
14. Lodise T.P., Lomaestro B.M., Drusano G.L., P.Society of Infectious Diseases Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006, 26:1320-1332.
15. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 2003, 17:479-501.
16. de Hoog M., Mouton J.W., van den Anker J.N. New dosing strategies for antibacterial agents in the neonate. Semin. Fetal Neonatal. Med. 2005, 10:185-194.
17. Muller A.E., DeJongh J., Bult Y., Goessens W.H., Mouton J.W., Danhof M., van den Anker J.N. Pharmacokinetics of penicillin G in infants with a gestational age of less than 32weeks. Antimicrob. Agents Chemother. 2007, 51:3720-3725.
18. Pullen J., de Rozario L., Stolk L.M., Degraeuwe P.L., van Tiel F.H., Zimmermann L.J. Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates. Ther. Drug Monit. 2006, 28:351-358.
19. Charles B.G., Preechagoon Y., Lee T.C., Steer P.A., Flenady V.J., Debuse N. Population pharmacokinetics of intravenous amoxicillin in very low birth weight infants. J. Pharm. Sci. 1997, 86:1288-1292.
20. Muller A.E., Oostvogel P.M., DeJongh J., Mouton J.W., Steegers E.A., Dorr P.J., Danhof M., Voskuyl R.A. Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera. Antimicrob. Agents Chemother. 2009, 53:1574-1580.
21. Li Z., Chen Y., Li Q., Cao D., Shi W., Cao Y., Wu D., Zhu Y., Wang Y., Chen C. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants. Eur. J. Clin. Pharmacol. 2013, 69:1223-1233.
22. Zobell J.T., Stockmann C., Young D.C., Cash J., McDowell B.J., Korgenski K., Sherwin C.M., Spigarelli M., Chatfield B.A., Ampofo K. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Clin. Ther. 2011, 33:1844-1850.
23. de Groot R., Hack B.D., Weber A., Chaffin D., Ramsey B., Smith A.L. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin. Pharmacol. Ther. 1990, 47:73-78.
24. Dudley M.N., Ambrose P.G., Bhavnani S.M., Craig W.A., Ferraro M.J., Jones R.N., C.Antimicrobial Susceptibility Testing Subcommittee of the, I.Laboratory Standards Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2013, 56:1301-1309.
25. Tamma P.D., Turnbull A.E., Milstone A.M., Hsu A.J., Carroll K.C., Cosgrove S.E. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?. Clin. Infect. Dis. 2012, 55:799-806.
26. Knoderer C.A., Saft S.A., Walker S.G., Rodefeld M.D., Turrentine M.W., Brown J.W., Healy D.P., Sowinski K.M. Cefuroxime pharmacokinetics in pediatric cardiovascular surgery patients undergoing cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. 2011, 25:425-430.
27. Iida S., Kawanishi T., Hayashi M. Indications for a ceftriaxone dosing regimen in Japanese paediatric patients using population pharmacokinetic/pharmacodynamic analysis and simulation. J. Pharm. Pharmacol. 2011, 63:65-72.
28. Ahsman M.J., Wildschut E.D., Tibboel D., Mathot R.A. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob. Agents Chemother. 2010, 54:1734-1741.
29. Buck M.L. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin. Pharmacokinet. 2003, 42:403-417.
30. Bradley J.S., Sauberan J.B., Ambrose P.G., Bhavnani S.M., Rasmussen M.R., Capparelli E.V. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr. Infect. Dis. J. 2008, 27:794-799.
31. Du X., Li C., Kuti J.L., Nightingale C.H., Nicolau D.P. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. J. Clin. Pharmacol. 2006, 46:69-75.
32. Ikawa K., Morikawa N., Ikeda K., Miki M., Kobayashi M. Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients. J. Infect. Chemother. 2010, 16:139-143.
33. van den Anker J.N., Pokorna P., Kinzig-Schippers M., Martinkova J., de Groot R., Drusano G.L., Sorgel F. Meropenem pharmacokinetics in the newborn. Antimicrob. Agents Chemother. 2009, 53:3871-3879.
34. Ohata Y., Tomita Y., Nakayama M., Kozuki T., Sunakawa K., Tanigawara Y. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations. Drug Metab. Pharmacokinet. 2011, 26:523-531.
35. Padari H., Metsvaht T., Korgvee L.T., Germovsek E., Ilmoja M.L., Kipper K., Herodes K., Standing J.F., Oselin K., Lutsar I. Short versus long infusion of meropenem in very-low-birth-weight neonates. Antimicrob. Agents Chemother. 2012, 56:4760-4764.
36. Parker E.M., Hutchison M., Blumer J.L. The pharmacokinetics of meropenem in infants and children: a population analysis. J. Antimicrob. Chemother. 1995, 36(Suppl. A):63-71.
37. Smith P.B., Cohen-Wolkowiez M., Castro L.M., Poindexter B., Bidegain M., Weitkamp J.H., Schelonka R.L., Ward R.M., Wade K., Valencia G., Burchfield D., Arrieta A., Bhatt-Mehta V., Walsh M., Kantak A., Rasmussen M., Sullivan J.E., Finer N., Brozanski B.S., Sanchez P., van den Anker J., Blumer J., Kearns G.L., Capparelli E.V., Anand R., Benjamin D.K., T.Meropenem Study Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr. Infect. Dis. J. 2011, 30:844-849.
38. Yoshizawa K., Ikawa K., Ikeda K., Ohge H., Morikawa N. Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children. Pediatr. Infect. Dis. J. 2013, 32:1208-1216.
39. Barclay M.L., Begg E.J., Chambers S.T. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrob. Agents Chemother. 1992, 36:1951-1957.
40. Barclay M.L., Begg E.J. Aminoglycoside adaptive resistance: importance for effective dosage regimens. Drugs 2001, 61:713-721.
41. Nielsen E.I., Sandstrom M., Honore P.H., Ewald U., Friberg L.E. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin. Pharmacokinet. 2009, 48:253-263.
42. Garcia B., Barcia E., Perez F., Molina I.T. Population pharmacokinetics of gentamicin in premature newborns. J. Antimicrob. Chemother. 2006, 58:372-379.
43. Botha J.H., du Preez M.J., Adhikari M. Population pharmacokinetics of gentamicin in South African newborns. Eur. J. Clin. Pharmacol. 2003, 59:755-759.
44. Vervelde M.L., Rademaker C.M., Krediet T.G., Fleer A., van Asten P., van Dijk A. Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen. Ther. Drug Monit. 1999, 21:514-519.
45. Izquierdo M., Lanao J.M., Cervero L., Jimenez N.V., Dominguez-Gil A. Population pharmacokinetics of gentamicin in premature infants. Ther. Drug Monit. 1992, 14:177-183.
46. Jensen P.D., Edgren B.E., Brundage R.C. Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model. Pharmacotherapy 1992, 12:178-182.
47. Mohamed A.F., Nielsen E.I., Cars O., Friberg L.E. Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob. Agents Chemother. 2012, 56:179-188.
48. Assael B.M., Parini R., Rusconi F., Cavanna G. Influence of intrauterine maturation on the pharmacokinetics of amikacin in the neonatal period. Pediatr. Res. 1982, 16:810-815.
49. Sardemann H., Colding H., Hendel J., Kampmann J.P., Hvidberg E.F., Vejlsgaard R. Kinetics and dose calculations of amikacin in the newborn. Clin. Pharmacol. Ther. 1976, 20:59-66.
50. Kafetzis D.A., Sinaniotis C.A., Papadatos C.J., Kosmidis J. Pharmacokinetics of amikacin in infants and pre-school children. Acta Paediatr. Scand. 1979, 68:419-422.
51. Sherwin C.M., Svahn S., Van der Linden A., Broadbent R.S., Medlicott N.J., Reith D.M. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur. J. Clin. Pharmacol. 2009, 65:705-713.
52. Hennig S., Norris R., Kirkpatrick C.M. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis-a population pharmacokinetic study. Br. J. Clin. Pharmacol. 2008, 65:502-510.
53. de Hoog M., Schoemaker R.C., Mouton J.W., van den Anker J.N. Tobramycin population pharmacokinetics in neonates. Clin. Pharmacol. Ther. 1997, 62:392-399.
54. Lam W., Tjon J., Seto W., Dekker A., Wong C., Atenafu E., Bitnun A., Waters V., Yau Y., Solomon M., Ratjen F. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. J. Antimicrob. Chemother. 2007, 59:1135-1140.
55. Touw D.J., Knox A.J., Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J. Cyst. Fibros. 2007, 6:327-333.
56. Rodriguez J.C., Schoenike S., Scott G.B., Rossique-Gonzalez M.T., Gomez-Marin O. An evaluation of gentamicin, tobramycin, and amikacin pharmacokinetic/pharmacodynamic parameters in HIV-infected children. J. Pediatr. Pharmacol. Ther. 2003, 8:274-283.
57. Giuliano R.A., Verpooten G.A., Verbist L., Wedeen R.P., De Broe M.E. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J. Pharmacol. Exp. Ther. 1986, 236:470-475.
58. Tulkens P.M. Nephrotoxicity of aminoglycoside antibiotics. Toxicol. Lett. 1989, 46:107-123.
59. Vandecasteele S.J., De Vriese A.S., Tacconelli E. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J. Antimicrob. Chemother. 2013, 68:743-748.
60. Anderson B.J., Allegaert K., Van den Anker J.N., Cossey V., Holford N.H. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br. J. Clin. Pharmacol. 2007, 63:75-84.
61. de Hoog M., Schoemaker R.C., Mouton J.W., van den Anker J.N. Vancomycin population pharmacokinetics in neonates. Clin. Pharmacol. Ther. 2000, 67:360-367.
62. Grimsley C., Thomson A.H. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch. Dis. Child. Fetal Neonatal Ed. 1999, 81:F221-F227.
63. Marques-Minana M.R., Saadeddin A., Peris J.E. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br. J. Clin. Pharmacol. 2010, 70:713-720.
64. Zhao W., Lopez E., Biran V., Durrmeyer X., Fakhoury M., Jacqz-Aigrain E. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch. Dis. Child. 2013, 98:449-453.
65. Tarral E., Jehl F., Tarral A., Simeoni U., Monteil H., Willard D., Geisert J. Pharmacokinetics of teicoplanin in children. J. Antimicrob. Chemother. 1988, 21(Suppl. A):47-51.
66. Terragna A., Ferrea G., Loy A., Danese A., Bernareggi A., Cavenaghi L., Rosina R. Pharmacokinetics of teicoplanin in pediatric patients. Antimicrob. Agents Chemother. 1988, 32:1223-1226.
67. Lukas J.C., Karikas G., Gazouli M., Kalabalikis P., Hatzis T., Macheras P. Pharmacokinetics of teicoplanin in an ICU population of children and infants. Pharm. Res. 2004, 21:2064-2071.
68. Preston S.L., Drusano G.L., Berman A.L., Fowler C.L., Chow A.T., Dornseif B., Reichl V., Natarajan J., Corrado M. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998, 279:125-129.
69. Burkhardt J.E., Hill M.A., Carlton W.W., Kesterson J.W. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet. Pathol. 1990, 27:162-170.
70. Payen S., Serreau R., Munck A., Aujard Y., Aigrain Y., Bressolle F., Jacqz-Aigrain E. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob. Agents Chemother. 2003, 47:3170-3178.
71. Rajagopalan P., Gastonguay M.R. Population pharmacokinetics of ciprofloxacin in pediatric patients. J. Clin. Pharmacol. 2003, 43:698-710.
72. Schaefer H.G., Stass H., Wedgwood J., Hampel B., Fischer C., Kuhlmann J., Schaad U.B. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob. Agents Chemother. 1996, 40:29-34.
73. Ambrose P.G., Grasela D.M., Grasela T.H., Passarell J., Mayer H.B., Pierce P.F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 2001, 45:2793-2797.
74. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 1993, 37:1073-1081.
75. Hassan H.E., Othman A.A., Eddington N.D., Duffy L., Xiao L., Waites K.B., Kaufman D.A., Fairchild K.D., Terrin M.L., Viscardi R.M. Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia. J. Clin. Pharmacol. 2011, 51:1264-1275.
76. Suyagh M., Collier P.S., Millership J.S., Iheagwaram G., Millar M., Halliday H.L., McElnay J.C. Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics 2011, 127:e367-e374.
77. Cohen-Wolkowiez M., Ouellet D., Smith P.B., James L.P., Ross A., Sullivan J.E., Walsh M.C., Zadell A., Newman N., White N.R., Kashuba A.D., Benjamin D.K. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob. Agents Chemother. 2012, 56:1828-1837.
78. Cohen-Wolkowiez M., Sampson M., Bloom B.T., Arrieta A., Wynn J.L., Martz K., Harper B., Kearns G.L., Capparelli E.V., Siegel D., Benjamin D.K., Smith P.B., N.on behalf of the Best Pharmaceuticals for Children Act - Pediatric Trials Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr. Infect. Dis. J. 2013, 32:956-961.
79. Kearns G.L., Abdel-Rahman S.M., Blumer J.L., Reed M.D., James L.P., Jacobs R.F., Bradley J.A., Welshman I.R., Jungbluth G.L., Stalker D.J., N.Pediatric Pharmacology Research Unit ingle dose pharmacokinetics of linezolid in infants and children. Pediatr. Infect. Dis. J. 2000, 19:1178-1184.
80. Rodriguez-Tudela J.L., Almirante B., Rodriguez-Pardo D., Laguna F., Donnelly J.P., Mouton J.W., Pahissa A., Cuenca-Estrella M. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob. Agents Chemother. 2007, 51:3599-3604.
81. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 2003, 47:1179-1186.
82. Saxen H., Hoppu K., Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin. Pharmacol. Ther. 1993, 54:269-277.
83. Kaufman D., Boyle R., Hazen K.C., Patrie J.T., Robinson M., Donowitz L.G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med. 2001, 345:1660-1666.
84. Kicklighter S.D., Springer S.C., Cox T., Hulsey T.C., Turner R.B. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001, 107:293-298.
85. Louie A., Liu Q.F., Drusano G.L., Liu W., Mayers M., Anaissie E., Miller M.H. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob. Agents Chemother. 1998, 42:1512-1514.
86. Piper L., Smith P.B., Hornik C.P., Cheifetz I.M., Barrett J.S., Moorthy G., Hope W.W., Wade K.C., Cohen-Wolkowiez M., Benjamin D.K. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr. Infect. Dis. J. 2011, 30:375-378.
87. Wu D., Wade K.C., Paul D.J., Barrett J.S. A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections. Ther. Drug Monit. 2009, 31:703-709.
88. Lee J.W., Seibel N.L., Amantea M., Whitcomb P., Pizzo P.A., Walsh T.J. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J. Pediatr. 1992, 120:987-993.
89. Bhandari V., Narang A., Kumar B., Singh M., Nair P.M., Bhakoo O.N. Itraconazole therapy for disseminated candidiasis in a very low birthweight neonate. J. Paediatr. Child Health 1992, 28:323-324.
90. Abdel-Rahman S.M., Jacobs R.F., Massarella J., Kauffman R.E., Bradley J.S., Kimko H.C., Kearns G.L., Shalayda K., Curtin C., Maldonado S.D., Blumer J.L. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob. Agents Chemother. 2007, 51:2668-2673.
91. Schmitt C., Perel Y., Harousseau J.L., Lemerle S., Chwetzoff E., le Moing J.P., Levron J.C. Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob. Agents Chemother. 2001, 45:1561-1564.
92. Foot A.B., Veys P.A., Gibson B.E. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant. 1999, 24:1089-1093.
93. Groll A.H., Wood L., Roden M., Mickiene D., Chiou C.C., Townley E., Dad L., Piscitelli S.C., Walsh T.J. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 2002, 46:2554-2563.
94. de Repentigny L., Ratelle J., Leclerc J.M., Cornu G., Sokal E.M., Jacqmin P., De Beule K. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob. Agents Chemother. 1998, 42:404-408.
95. Andes D., Pascual A., Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 2009, 53:24-34.
96. Lestner J.M., Roberts S.A., Moore C.B., Howard S.J., Denning D.W., Hope W.W. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin. Infect. Dis. 2009, 49:928-930.
97. Hope W.W., Billaud E.M., Lestner J., Denning D.W. Therapeutic drug monitoring for triazoles. Curr. Opin. Infect. Dis. 2008, 21:580-586.
98. Groll A.H., Jaeger G., Allendorf A., Herrmann G., Schloesser R., von Loewenich V. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin. Infect. Dis. 1998, 27:437-452.
99. Doby E.H., Benjamin D.K., Blaschke A.J., Ward R.M., Pavia A.T., Martin P.L., Driscoll T.A., Cohen-Wolkowiez M., Moran C. Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr. Infect. Dis. J. 2012, 31:632-635.
100. Kohli V., Taneja V., Sachdev P., Joshi R. Voriconazole in newborns. Indian Pediatr. 2008, 45:236-238.
101. Hope W.W. Population pharmacokinetics of voriconazole in adults. Antimicrob. Agents Chemother. 2012, 56:526-531.
102. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., Kern W.V., Marr K.A., Ribaud P., Lortholary O., Sylvester R., Rubin R.H., Wingard J.R., Stark P., Durand C., Caillot D., Thiel E., Chandrasekar P.H., Hodges M.R., Schlamm H.T., Troke P.F., de Pauw B., R.Invasive Fungal, Infections Group of the European Organisation for, C.Treatment of, G.the Global Aspergillus Study Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 2002, 347:408-415.
103. Driscoll T.A., Yu L.C., Frangoul H., Krance R.A., Nemecek E., Blumer J., Arrieta A., Graham M.L., Bradfield S.M., Baruch A., Liu P. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob. Agents Chemother. 2011, 55:5770-5779.
104. Driscoll T.A., Frangoul H., Nemecek E.R., Murphey D.K., Yu L.C., Blumer J., Krance R.A., Baruch A., Liu P. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. Antimicrob. Agents Chemother. 2011, 55:5780-5789.
105. Karlsson M.O., Lutsar I., Milligan P.A. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 2009, 53:935-944.
106. Neely M., Rushing T., Kovacs A., Jelliffe R., Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 2010, 50:27-36.
107. Friberg L.E., Ravva P., Karlsson M.O., Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob. Agents Chemother. 2012, 56:3032-3042.
108. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 2008, 46:201-211.
109. Krishna G., Sansone-Parsons A., Martinho M., Kantesaria B., Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob. Agents Chemother. 2007, 51:812-818.
110. Lewis R.E. Pharmacodynamic implications for use of antifungal agents. Curr. Opin. Pharmacol. 2007, 7:491-497.
111. Saez-Llorens X., Macias M., Maiya P., Pineros J., Jafri H.S., Chatterjee A., Ruiz G., Raghavan J., Bradshaw S.K., Kartsonis N.A., Sun P., Strohmaier K.M., Fallon M., Bi S., Stone J.A., Chow J.W. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3months of age. Antimicrob. Agents Chemother. 2009, 53:869-875.
112. Walsh T.J., Adamson P.C., Seibel N.L., Flynn P.M., Neely M.N., Schwartz C., Shad A., Kaplan S.L., Roden M.M., Stone J.A., Miller A., Bradshaw S.K., Li S.X., Sable C.A., Kartsonis N.A. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 2005, 49:4536-4545.
113. Li C.C., Sun P., Dong Y., Bi S., Desai R., Dockendorf M.F., Kartsonis N.A., Ngai A.L., Bradshaw S., Stone J.A. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob. Agents Chemother. 2011, 55:2098-2105.
114. Hope W.W., Smith P.B., Arrieta A., Buell D.N., Roy M., Kaibara A., Walsh T.J., Cohen-Wolkowiez M., Benjamin D.K. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob. Agents Chemother. 2010, 54:2633-2637.
115. Hope W.W., Seibel N.L., Schwartz C.L., Arrieta A., Flynn P., Shad A., Albano E., Keirns J.J., Buell D.N., Gumbo T., Drusano G.L., Walsh T.J. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother. 2007, 51:3714-3719.
116. Seibel N.L., Schwartz C., Arrieta A., Flynn P., Shad A., Albano E., Keirns J., Lau W.M., Facklam D.P., Buell D.N., Walsh T.J. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 2005, 49:3317-3324.
117. Benjamin D.K., Driscoll T., Seibel N.L., Gonzalez C.E., Roden M.M., Kilaru R., Clark K., Dowell J.A., Schranz J., Walsh T.J. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 2006, 50:632-638.
118. Dowell J.A., Knebel W., Ludden T., Stogniew M., Krause D., Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 2004, 44:590-598.
119. Starke J.R., Mason E.O., Kramer W.G., Kaplan S.L. Pharmacokinetics of amphotericin B in infants and children. J. Infect. Dis. 1987, 155:766-774.
120. Benson J.M., Nahata M.C. Pharmacokinetics of amphotericin B in children. Antimicrob. Agents Chemother. 1989, 33:1989-1993.
121. Baley J.E., Meyers C., Kliegman R.M., Jacobs M.R., Blumer J.L. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J. Pediatr. 1990, 116:791-797.
122. Wurthwein G., Groll A.H., Hempel G., Adler-Shohet F.C., Lieberman J.M., Walsh T.J. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob. Agents Chemother. 2005, 49:5092-5098.
123. Hong Y., Shaw P.J., Nath C.E., Yadav S.P., Stephen K.R., Earl J.W., McLachlan A.J. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob. Agents Chemother. 2006, 50:935-942.
124. Kimberlin D.W. Antiviral therapies in children: has their time arrived?. Pediatr. Clin. N. Am. 2005, 52:837-867. (vii).
125. Hintz M., Connor J.D., Spector S.A., Blum M.R., Keeney R.E., Yeager A.S. Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. Am. J. Med. 1982, 73:210-214.
126. Sullender W.M., Arvin A.M., Diaz P.S., Connor J.D., Straube R., Dankner W., Levin M.J., Weller S., Blum M.R., Chapman S. Pharmacokinetics of acyclovir suspension in infants and children. Antimicrob. Agents Chemother. 1987, 31:1722-1726.
127. Fletcher C.V., Englund J.A., Bean B., Chinnock B., Brundage D.M., Balfour H.H. Continuous infusion of high-dose acyclovir for serious herpesvirus infections. Antimicrob. Agents Chemother. 1989, 33:1375-1378.
128. Meszner Z., Nyerges G., Bell A.R. Oral acyclovir to prevent dissemination of varicella in immunocompromised children. J. Infect. 1993, 26:9-15.
129. Rudd C., Rivadeneira E.D., Gutman L.T. Dosing considerations for oral acyclovir following neonatal herpes disease. Acta Paediatr. 1994, 83:1237-1243.
130. Tod M., Lokiec F., Bidault R., De Bony F., Petitjean O., Aujard Y. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob. Agents Chemother. 2001, 45:150-157.
131. Bomgaars L., Thompson P., Berg S., Serabe B., Aleksic A., Blaney S. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. Pediatr. Blood Cancer 2008, 51:504-508.
132. Zeng L., Nath C.E., Blair E.Y., Shaw P.J., Stephen K., Earl J.W., Coakley J.C., McLachlan A.J. Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. Antimicrob. Agents Chemother. 2009, 53:2918-2927.
133. Saez-Llorens X., Yogev R., Arguedas A., Rodriguez A., Spigarelli M.G., De Leon Castrejon T., Bomgaars L., Roberts M., Abrams B., Zhou W., Looby M., Kaiser G., Hamed K. Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob. Agents Chemother. 2009, 53:1912-1920.
134. Blumer J., Rodriguez A., Sanchez P.J., Sallas W., Kaiser G., Hamed K. Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. Antimicrob. Agents Chemother. 2010, 54:2032-2041.
135. Ogungbenro K., Matthews I., Looby M., Kaiser G., Graham G., Aarons L. Population pharmacokinetics and optimal design of paediatric studies for famciclovir. Br. J. Clin. Pharmacol. 2009, 68:546-560.
136. Pescovitz M.D., Brook B., Jindal R.M., Leapman S.B., Milgrom M.L., Filo R.S. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study. Clin. Transpl. 1997, 11:613-617.
137. Filler G., Lampe D., von Bredow M.A., Lappenberg-Pelzer M., Rocher S., Strehlau J., Ehrich J.H. Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. Pediatr. Nephrol. 1998, 12:6-9.
138. Zhang D., Lapeyraque A.L., Popon M., Loirat C., Jacqz-Aigrain E. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. Pediatr. Nephrol. 2003, 18:943-948.
139. Jacqz-Aigrain E., Macher M.A., Sauvageon-Marthe H., Brun P., Loirat C. Pharmacokinetics of ganciclovir in renal transplant children. Pediatr. Nephrol. 1992, 6:194-196.
140. Vaudry W., Ettenger R., Jara P., Varela-Fascinetto G., Bouw M.R., Ives J., Walker R., Valcyte W.V.S.G. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am. J. Transplant. 2009, 9:636-643.
141. Pescovitz M.D., Ettenger R.B., Strife C.F., Sherbotie J.R., Thomas S.E., McDiarmid S., Bartosh S., Ives J., Bouw M.R., Bucuvalas J. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl. Infect. Dis. 2010, 12:195-203.
142. Vezina H.E., Brundage R.C., Nevins T.E., Balfour H.H. The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein-Barr virus disease. Clin. Pharmacol. Adv. Appl. 2010, 2:1-7.
143. Luck S., Lovering A., Griffiths P., Sharland M. Ganciclovir treatment in children: evidence of subtherapeutic levels. Int. J. Antimicrob. Agents 2011, 37:445-448.
144. Frenkel L.M., Capparelli E.V., Dankner W.M., Xu J., Smith I.L., Ballow A., Culnane M., Read J.S., Thompson M., Mohan K.M., Shaver A., Robinson C.A., Stempien M.J., Burchett S.K., Melvin A.J., Borkowsky W., Petru A., Kovacs A., Yogev R., Goldsmith J., McFarland E.J., Spector S.A. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group. J. Infect. Dis. 2000, 182:1616-1624.
145. Kimberlin D.W., Acosta E.P., Sanchez P.J., Sood S., Agrawal V., Homans J., Jacobs R.F., Lang D., Romero J.R., Griffin J., Cloud G.A., Lakeman F.D., Whitley R.J., A.National Institute of, G.Infectious Diseases Collaborative Antiviral Study Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J. Infect. Dis. 2008, 197:836-845.
146. Englund J.A., Piedra P.A., Jefferson L.S., Wilson S.Z., Taber L.H., Gilbert B.E. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J. Pediatr. 1990, 117:313-320.
147. Lankester A.C., Heemskerk B., Claas E.C., Schilham M.W., Beersma M.F., Bredius R.G., van Tol M.J., Kroes A.C. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin. Infect. Dis. 2004, 38:1521-1525.
148. Hosoya M., Mori S., Tomoda A., Mori K., Sawaishi Y., Kimura H., Shigeta S., Suzuki H. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob. Agents Chemother. 2004, 48:4631-4635.
149. McJunkin J.E., Nahata M.C., De Los Reyes E.C., Hunt W.G., Caceres M., Khan R.R., Chebib M.G., Taravath S., Minnich L.L., Carr R., Welch C.A., Whitley R.J. Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis. Pediatr. Infect. Dis. J. 2011, 30:860-865.
150. Gonzalez-Peralta R.P., Kelly D.A., Haber B., Molleston J., Murray K.F., Jonas M.M., Shelton M., Mieli-Vergani G., Lurie Y., Martin S., Lang T., Baczkowski A., Geffner M., Gupta S., Laughlin M., C.T.G.International Pediatric Hepatitis Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005, 42:1010-1018.
151. Oxford J. Oseltamivir in the management of influenza. Expert. Opin. Pharmacother. 2005, 6:2493-2500.
152. Standing J.F., Tsolia M., Lutsar I. Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children. Infect. Disord. Drug Targets 2013, 13:6-14.
153. Kimberlin D.W., Acosta E.P., Prichard M.N., Sanchez P.J., Ampofo K., Lang D., Ashouri N., Vanchiere J.A., Abzug M.J., Abughali N., Caserta M.T., Englund J.A., Sood S.K., Spigarelli M.G., Bradley J.S., Lew J., Michaels M.G., Wan W., Cloud G., Jester P., Lakeman F.D., Whitley R.J., A.National Institute of, G.Infectious Diseases Collaborative Antiviral Study Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2years with influenza. J. Infect. Dis. 2013, 207:709-720.
154. Sugaya N., Kohno S., Ishibashi T., Wajima T., Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob. Agents Chemother. 2012, 56:369-377.
155. Neely M.N., Rakhmanina N.Y. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin. Pharmacokinet. 2011, 50:143-189.
156. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
157. Palumbo P., Wu H., Chadwick E., Ruan P., Luzuriaga K., Rodman J., Yogev R., A.C.T.G.I.Pediatric Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection. J. Infect. Dis. 2007, 196:23-29.
158. De Beaudrap P., Rouet F., Fassinou P., Kouakoussui A., Mercier S., Ecochard R., Msellati P. CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Cote d'Ivoire. J. Acquir. Immune Defic. Syndr. 2008, 49:70-76.
159. Lewis J., Walker A.S., Castro H., De Rossi A., Gibb D.M., Giaquinto C., Klein N., Callard R. Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J. Infect. Dis. 2012, 205:548-556.
160. + T-cell count recovery in HIV-infected adults is reversed in children: higher thymic output may be responsible. Clin. Infect. Dis. 2012, 55:304-307. (author reply 307).
161. Sabin C.A., Smith C.J., d'Arminio Monforte A., Battegay M., Gabiano C., Galli L., Geelen S., Gibb D., Guiguet M., Judd A., Leport C., Dabis F., Pantazis N., Porter K., Raffi F., Thorne C., Torti C., Walker S., Warszawski J., Wintergerst U., Chene G., Lundgren J. Response to combination antiretroviral therapy: variation by age. Aids 2008, 22:1463-1473. H.I.V.E.R.E.S.G. Collaboration of Observational.
162. Thiebaut R., Jacqmin-Gadda H., Walker S., Sabin C., Prins M., Del Amo J., Porter K., Dabis F., Chene G., Collaboration C. Determinants of response to first HAART regimen in antiretroviral-naive patients with an estimated time since HIV seroconversion. HIV Med. 2006, 7:1-9.
163. Drylewicz J., Commenges D., Thiebaut R. Score tests for exploring complex models: application to HIV dynamics models. Biom. J. 2010, 52:10-21.
164. Putter H., Heisterkamp S.H., Lange J.M., de Wolf F. A Bayesian approach to parameter estimation in HIV dynamical models. Stat. Med. 2002, 21:2199-2214.
165. Guedj J., Thiebaut R., Commenges D. Maximum likelihood estimation in dynamical models of HIV. Biometrics 2007, 63:1198-1206.
166. Lavielle M., Samson A., Karina Fermin A., Mentre F. Maximum likelihood estimation of long-term HIV dynamic models and antiviral response. Biometrics 2011, 67:250-259.
167. + cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin. Infect. Dis. 2009, 48:787-794.
168. Rong L., Perelson A.S. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput. Biol. 2009, 5:e1000533.
169. Krakovska O., Wahl L.M. Drug-sparing regimens for HIV combination therapy: benefits predicted for "drug coasting". Bull. Math. Biol. 2007, 69:2627-2647.
170. + T cells: mathematical analysis of one phase I study in HIV-1 infected patients. Conference Poster at Systems Approaches in Immunology 2010, (Santa Fe, NM, USA).
171. Garrido C., Rallon N., Soriano V., Lopez M., Zahonero N., de Mendoza C., Benito J.M. Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. Aids 2012, 26:551-557.
172. Bouazza N., Treluyer J.M., Msellati P., Van de Perre P., Diagbouga S., Nacro B., Hien H., Zoure E., Rouet F., Ouiminga A., Blanche S., Hirt D., Urien S. A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients. Aids 2013, 27:761-768.
173. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection Available at, (Last accessed 30th June 2013). http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf.
174. Committee P.S., Welch S., Sharland M., Lyall E.G., Tudor-Williams G., Niehues T., Wintergerst U., Bunupuradah T., Hainaut M., Della Negra M., Pena M.J., Amador J.T., Gattinara G.C., Compagnucci A., Faye A., Giaquinto C., Gibb D.M., Gandhi K., Forcat S., Buckberry K., Harper L., Konigs C., Patel D., Bastiaans D. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009, 10:591-613.
175. Prague M., Commenges D., Drylewicz J., Thiebaut R. Treatment monitoring of HIV-infected patients based on mechanistic models. Biometrics 2012, 68:902-911.
176. Charrier E., Cordeiro P., Brito R.M., Mezziani S., Herblot S., Le Deist F., Duval M. Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children. Bone Marrow Transplant. 2013, 48:376-382.
177. + cell count and transplant-related mortality. Bone Marrow Transplant. 2008, 41:55-62.
178. Schwinger W., Weber-Mzell D., Zois B., Rojacher T., Benesch M., Lackner H., Dornbusch H.J., Sovinz P., Moser A., Lanzer G., Schauenstein K., Ofner P., Handgretinger R., Urban C. Immune reconstitution after purified autologous and allogeneic blood stem cell transplantation compared with unmanipulated bone marrow transplantation in children. Br. J. Haematol. 2006, 135:76-84.
179. Bartelink I.H., Belitser S.V., Knibbe C.A., Danhof M., de Pagter A.J., Egberts T.C., Boelens J.J. Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol. Blood Marrow Transplant. 2013, 19:305-313.
180. Kim H.O., Oh H.J., Lee J.W., Jang P.S., Chung N.G., Cho B., Kim H.K. Immune reconstitution after allogeneic hematopoietic stem cell transplantation in children: a single institution study of 59 patients. Korean J. Pediatr. 2013, 56:26-31.
181. Chen X., Hale G.A., Barfield R., Benaim E., Leung W.H., Knowles J., Horwitz E.M., Woodard P., Kasow K., Yusuf U., Behm F.G., Hayden R.T., Shurtleff S.A., Turner V., Srivastava D.K., Handgretinger R. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br. J. Haematol. 2006, 135:524-532.
182. + lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. Blood Transfus. 2012, 10:174-180.
183. Tedeschi S.K., Jagasia M., Engelhardt B.G., Domm J., Kassim A.A., Chinratanalab W., Greenhut S.L., Goodman S., Greer J.P., Schuening F., Frangoul H., Savani B.N. Early lymphocyte reconstitution is associated with improved transplant outcome after cord blood transplantation. Cytotherapy 2011, 13:78-82.
184. Koenig M., Huenecke S., Salzmann-Manrique E., Esser R., Quaritsch R., Steinhilber D., Radeke H.H., Martin H., Bader P., Klingebiel T., Schwabe D., Schneider G., Lehrnbecher T., Orth A., Koehl U. Multivariate analyses of immune reconstitution in children after allo-SCT: risk-estimation based on age-matched leukocyte sub-populations. Bone Marrow Transplant. 2010, 45:613-621.
185. Renard C., Barlogis V., Mialou V., Galambrun C., Bernoux D., Goutagny M.P., Glasman L., Loundou A.D., Poitevin-Later F., Dignat-George F., Dubois V., Picard C., Chabannon C., Bertrand Y., Michel G. Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children. Br. J. Haematol. 2011, 152:322-330.
186. + count reconstitution is associated with survival. Bone Marrow Transplant. 2007, 39:269-278.
187. Duval M., Pedron B., Rohrlich P., Legrand F., Faye A., Lescoeur B., Bensaid P., Larchee R., Sterkers G., Vilmer E. Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin. Bone Marrow Transplant. 2002, 30:421-426.
188. Barlogis V., Glasman L., Brunet C., Loundou A.D., Lemarie C., Galambrun C., Thuret I., Curtillet C., Le Meignen M., Bernard F., Chambost H., Calmels B., Picard C., Chabannon C., Dignat-George F., Michel G. Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in children. Biol. Blood Marrow Transplant. 2011, 17:109-116.
189. + T lymphocyte counts affects overall survival after pediatric allogeneic hematopoietic stem cell transplantation. J. Pediatr. Hematol. Oncol. 2012, 34:29-34.
190. Huenecke S., Behl M., Fadler C., Zimmermann S.Y., Bochennek K., Tramsen L., Esser R., Klarmann D., Kamper M., Sattler A., von Laer D., Klingebiel T., Lehrnbecher T., Koehl U. Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis. Eur. J. Haematol. 2008, 80:532-539.
191. Olkinuora H., von Willebrand E., Kantele J.M., Vainio O., Talvensaari K., Saarinen-Pihkala U., Siitonen S., Vettenranta K. The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. Scand. J. Immunol. 2011, 73:586-593.
192. Clave E., Busson M., Douay C., Peffault de Latour R., Berrou J., Rabian C., Carmagnat M., Rocha V., Charron D., Socie G., Toubert A. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood 2009, 113:6477-6484.
193. Fallen P.R., McGreavey L., Madrigal J.A., Potter M., Ethell M., Prentice H.G., Guimaraes A., Travers P.J. Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant. 2003, 32:1001-1014.
194. Surh C.D., Sprent J. Homeostasis of naive and memory T cells. Immunity 2008, 29:848-862.
195. Plunkett W., Gandhi V., Huang P., Robertson L.E., Yang L.Y., Gregoire V., Estey E., Keating M.J. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin. Oncol. 1993, 20:2-12.
196. Salinger D.H., Blough D.K., Vicini P., Anasetti C., O'Donnell P.V., Sandmaier B.M., McCune J.S. A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. Clin. Cancer. Res. 2009, 15:5280-5287.
197. Tasso M.J., Boddy A.V., Price L., Wyllie R.A., Pearson A.D., Idle J.R. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother. Pharmacol. 1992, 30:207-211.
198. van Hasselt J.G., van Eijkelenburg N.K., Beijnen J.H., Schellens J.H., Huitema A.D. Optimizing drug development of anti-cancer drugs in children using modelling and simulation. Br. J. Clin. Pharmacol. 2013, 76:30-47.
199. Glowka F.K., Karazniewicz-Lada M., Grund G., Wrobel T., Wachowiak J. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone Marrow Transplant. 2008, 42(Suppl. 2):S67-S70.
200. Elter T., Molnar I., Kuhlmann J., Hallek M., Wendtner C. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk. Lymphoma 2008, 49:2256-2262.
201. Call S.K., Kasow K.A., Barfield R., Madden R., Leung W., Horwitz E., Woodard P., Panetta J.C., Baker S., Handgretinger R., Rodman J., Hale G.A. Total and active rabbit antithymocyte globulin (rATG; Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol. Blood Marrow Transplant. 2009, 15:274-278.
202. Seidel M.G., Fritsch G., Matthes-Martin S., Lawitschka A., Lion T., Potschger U., Rosenmayr A., Fischer G., Gadner H., Peters C. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J. Pediatr. Hematol. Oncol. 2005, 27:532-536.
203. Willemze A.J., Cremers S.C., Schoemaker R.C., Lankester A.C., den Hartigh J., Burggraaf J., Vossen J.M. Ciclosporin kinetics in children after stem cell transplantation. Br. J. Clin. Pharmacol. 2008, 66:539-545.
204. Downing H.J., Pirmohamed M., Beresford M.W., Smyth R.L. Paediatric use of mycophenolate mofetil. Br. J. Clin. Pharmacol. 2013, 75:45-59.